comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 21:04:09 - browse：74432

Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： In early work, researchers turn to CRISPR to treat Alzheimer's

leisure time

WSS

A public scorecard can help hold safety

Medicare innovation center doesn’t save money, experts say

Experts study whether long Covid risk adds up with each reinfection

A public scorecard can help hold safety

The United States is paying nearly triple for new Covid vaccines

Flu, Covid vaccination rates decline, new survey data show

Wikipedia

comprehensive

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Sanders adds drug shortage policies to pandemic preparedness bill

Apple is now the first public company to be valued at $3 trillion

The Karikó problem: Lessons for funding basic research

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Group opposing PBM reform sets lobbying record

Continuity nursing helped my family in our darkest PICU moments

The United States is paying nearly triple for new Covid vaccines

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

FDA approves RSV monoclonal antibody for infants, toddlers

Key House panel plots a new health care package

A public scorecard can help hold safety

The stability of $0 premiums in Medicare Advantage

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

What will Novo Nordisk's VC do with its influx of cash?

entertainment

explore

leisure time

knowledge